Published online before print March 30, 2006, doi: 10.1161/01.RES.0000219901.13974.15
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on November 1, 2005
Revised on March 9, 2006
Accepted on March 22, 2006
Critical Roles of Muscle-Secreted Angiogenic Factors in Therapeutic Neovascularization
Kaoru Tateno ;
From the Departments of Cardiovascular Science and Medicine (K.T., T.M., H.T., H.A., S.T., T.K., H.M., T.O., K.M., J.-i.N., Y. Kobayashi, T.N., Y. Kuwabara, I.K.), Clinical Cell Biology (N.S., Y.S.), and Molecular Diagnosis (F.N.), Chiba University Graduate School of Medicine, Japan; and Division of Cell Biology (Y.I.), Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, Japan.
* To whom correspondence should be addressed. E-mail: komuro-tky{at}umin.ac.jp.
The discovery of bone marrow-derived endothelial progenitors in the peripheral blood has promoted intensive studies on the potential of cell therapy for various human diseases. Accumulating evidence has suggested that implantation of bone marrow mononuclear cells effectively promotes neovascularization in ischemic tissues. It has also been reported that the implanted cells are incorporated not only into the newly formed vessels but also secrete angiogenic factors. However, the mechanism by which cell therapy improves tissue ischemia remains obscure. We enrolled 29 "no-option" patients with critical limb ischemia and treated ischemic limbs by implantation of peripheral mononuclear cells. Cell therapy using peripheral mononuclear cells was very effective for the treatment of limb ischemia, and its efficacy was associated with increases in the plasma levels of angiogenic factors, in particular interleukin-1
(IL-1). We then examined an experimental model of limb ischemia using IL-1-deficient mice. Implantation of IL-1-deficient mononuclear cells improved tissue ischemia as efficiently as that of wild-type cells. Both wild-type and IL-1-deficient mononuclear cells increased expression of IL-1 and thus induced angiogenic factors in muscle cells of ischemic limbs to a similar extent. In contrast, inability of muscle cells to secrete IL-1 markedly reduces induction of angiogenic factors and impairs neovascularization by cell implantation. Implanted cells do not secret angiogenic factors sufficient for neovascularization but, instead, stimulate muscle cells to produce angiogenic factors, thereby promoting neovascularization in ischemic tissues. Further studies will allow us to develop more effective treatments for ischemic vascular disease.
Key words: angiogenesis • interleukins • muscles
Related Article:
- Therapeutic Angiogenesis: Another Passing Phase?
- Gregg L. Semenza
Circ. Res. 2006 98: 1115-1116.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
 |
|
 |
|
  D. Zisa, A. Shabbir, M. Mastri, G. Suzuki, and T. Lee Intramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cells Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2009; 297(5): R1503 - R1515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yamamoto, T. Matsuura, G. Narazaki, M. Sugitani, K. Tanaka, A. Maeda, G. Shiota, K. Sato, A. Yoshida, and I. Hisatome Synergistic effects of autologous cell and hepatocyte growth factor gene therapy for neovascularization in a murine model of hindlimb ischemia Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1329 - H1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-S. Li, M. Kubo, K. Ueda, M. Murakami, M. Ohshima, T. Kobayashi, T. Tanaka, B. Shirasawa, A. Mikamo, and K. Hamano Identification of Risk Factors Related to Poor Angiogenic Potency of Bone Marrow Cells From Different Patients Circulation, September 15, 2009; 120(11_suppl_1): S255 - S261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yoshida, T. Kitaichi, M. Urata, H. Kurobe, T. Kanbara, T. Motoki, and T. Kitagawa Syngeneic bone marrow mononuclear cells improve pulmonary arterial hypertension through vascular endothelial growth factor upregulation. Ann. Thorac. Surg., August 1, 2009; 88(2): 418 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, H. Okada, G. Takemura, M. Esaki, H. Kobayashi, H. Kanamori, I. Kawamura, R. Maruyama, T. Fujiwara, H. Fujiwara, et al. Sustained Release of Erythropoietin Using Biodegradable Gelatin Hydrogel Microspheres Persistently Improves Lower Leg Ischemia J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2378 - 2388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Moriya, T. Minamino, K. Tateno, N. Shimizu, Y. Kuwabara, Y. Sato, Y. Saito, and I. Komuro Long-Term Outcome of Therapeutic Neovascularization Using Peripheral Blood Mononuclear Cells for Limb Ischemia Circ Cardiovasc Interv, June 1, 2009; 2(3): 245 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shabbir, D. Zisa, G. Suzuki, and T. Lee Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1888 - H1897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Mohri, Y. Fujio, M. Obana, T. Iwakura, K. Matsuda, M. Maeda, and J. Azuma Signals Through Glycoprotein 130 Regulate the Endothelial Differentiation of Cardiac Stem Cells Arterioscler Thromb Vasc Biol, May 1, 2009; 29(5): 754 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Al Mheid and A. A. Quyyumi Cell Therapy in Peripheral Arterial Disease Angiology, January 1, 2009; 59(6): 705 - 716. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Shiba, M. Takahashi, T. Hata, H. Murayama, H. Morimoto, H. Ise, T. Nagasawa, and U. Ikeda Bone marrow CXCR4 induction by cultivation enhances therapeutic angiogenesis Cardiovasc Res, January 1, 2009; 81(1): 169 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Urano, Y. Ito, M. Akao, T. Sawa, K. Miyata, M. Tabata, T. Morisada, T. Hato, M. Yano, T. Kadomatsu, et al. Angiopoietin-Related Growth Factor Enhances Blood Flow Via Activation of the ERK1/2-eNOS-NO Pathway in a Mouse Hind-Limb Ischemia Model Arterioscler Thromb Vasc Biol, May 1, 2008; 28(5): 827 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Wang, W.-J. Cherng, N.-I Yang, L.-T. Kuo, C.-M. Hsu, H.-I Yeh, Y.-J. Lan, C.-H. Yeh, and W. L. Stanford Late-Outgrowth Endothelial Cells Attenuate Intimal Hyperplasia Contributed by Mesenchymal Stem Cells After Vascular Injury Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 54 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Cho, N. Lee, J. Y. Lee, Y. J. Choi, M. Ii, A. Wecker, J.-O. Jeong, C. Curry, G. Qin, and Y.-s. Yoon Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart J. Exp. Med., December 24, 2007; 204(13): 3257 - 3269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Vartanian and R. Sarkar Therapeutic Angiogenesis Vascular and Endovascular Surgery, July 1, 2007; 41(3): 173 - 185. [Abstract] [PDF]
|
|
|
|
|
|
M. Sumi, M. Sata, S.-i. Miura, K.-A. Rye, N. Toya, Y. Kanaoka, K. Yanaga, T. Ohki, K. Saku, and R. Nagai Reconstituted High-Density Lipoprotein Stimulates Differentiation of Endothelial Progenitor Cells and Enhances Ischemia-Induced Angiogenesis Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 813 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Semenza Therapeutic Angiogenesis: Another Passing Phase? Circ. Res., May 12, 2006; 98(9): 1115 - 1116. [Full Text] [PDF]
|
|